BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 27175732)

  • 1. Possibilities and challenges for developing a successful vaccine for leishmaniasis.
    Srivastava S; Shankar P; Mishra J; Singh S
    Parasit Vectors; 2016 May; 9(1):277. PubMed ID: 27175732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
    Osman M; Mistry A; Keding A; Gabe R; Cook E; Forrester S; Wiggins R; Di Marco S; Colloca S; Siani L; Cortese R; Smith DF; Aebischer T; Kaye PM; Lacey CJ
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Status of vaccine research and development of vaccines for leishmaniasis.
    Gillespie PM; Beaumier CM; Strych U; Hayward T; Hotez PJ; Bottazzi ME
    Vaccine; 2016 Jun; 34(26):2992-2995. PubMed ID: 26973063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Approaches and problems in vaccine development against leishmaniasis].
    Allahverdiyev A; Bağirova M; Cakir Koç R; Oztel ON; Elçıçek S; Ateş SC; Karaca TD
    Turkiye Parazitol Derg; 2010; 34(2):122-30. PubMed ID: 20597059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines for leishmaniasis in the fore coming 25 years.
    Palatnik-de-Sousa CB
    Vaccine; 2008 Mar; 26(14):1709-24. PubMed ID: 18295939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine candidates for leishmaniasis: a review.
    Nagill R; Kaur S
    Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccines for visceral leishmaniasis: A review.
    Jain K; Jain NK
    J Immunol Methods; 2015 Jul; 422():1-12. PubMed ID: 25858230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leishmania Vaccines: the Current Situation with Its Promising Aspect for the Future.
    Dinc R
    Korean J Parasitol; 2022 Dec; 60(6):379-391. PubMed ID: 36588414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetically modified live attenuated vaccine: A potential strategy to combat visceral leishmaniasis.
    Pandey SC; Kumar A; Samant M
    Parasite Immunol; 2020 Sep; 42(9):e12732. PubMed ID: 32418227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.
    Selvapandiyan A; Dey R; Gannavaram S; Solanki S; Salotra P; Nakhasi HL
    Vaccine; 2014 Jun; 32(31):3895-901. PubMed ID: 24837513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress towards a Leishmania vaccine.
    Tabbara KS
    Saudi Med J; 2006 Jul; 27(7):942-50. PubMed ID: 16830009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review on the Drug Intolerance and Vaccine Development for the Leishmaniasis.
    Kumari P; Mamud A; Jha AN
    Curr Drug Targets; 2023; 24(13):1023-1031. PubMed ID: 37823567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum.
    Fiuza JA; Gannavaram S; Santiago Hda C; Selvapandiyan A; Souza DM; Passos LS; de Mendonça LZ; Lemos-Giunchetti Dda S; Ricci ND; Bartholomeu DC; Giunchetti RC; Bueno LL; Correa-Oliveira R; Nakhasi HL; Fujiwara RT
    Vaccine; 2015 Jan; 33(2):280-8. PubMed ID: 25475955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Immunopathogenesis in Cutaneous Leishmaniasis And Post Kala-azar Dermal Leishmaniasis (PKDL).
    Volpedo G; Pacheco-Fernandez T; Holcomb EA; Cipriano N; Cox B; Satoskar AR
    Front Cell Infect Microbiol; 2021; 11():685296. PubMed ID: 34169006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmaniasis: current status of vaccine development.
    Handman E
    Clin Microbiol Rev; 2001 Apr; 14(2):229-43. PubMed ID: 11292637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine candidates against leishmania under current research.
    Iborra S; Solana JC; Requena JM; Soto M
    Expert Rev Vaccines; 2018 Apr; 17(4):323-334. PubMed ID: 29589966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines against leishmaniasis.
    Modabber F
    Ann Trop Med Parasitol; 1995 Dec; 89 Suppl 1():83-8. PubMed ID: 8745930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serodiagnosis of leishmaniasis.
    Kar K
    Crit Rev Microbiol; 1995; 21(2):123-52. PubMed ID: 7639932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in vaccines for leishmaniasis.
    Requena JM; Iborra S; Carrión J; Alonso C; Soto M
    Expert Opin Biol Ther; 2004 Sep; 4(9):1505-17. PubMed ID: 15335317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.